Login to Your Account

Akarna lands $15M in series B round for NASH candidate

By Michael Fitzhugh
Staff Writer

Tuesday, February 16, 2016

Akarna Therapeutics Ltd. closed a $15 million series B preferred stock financing that the company said would accelerate the development of its lead farnesoid X receptor (FXR) agonist drug candidate through human proof-of-concept studies in patients with non-alcoholic steatohepatitis (NASH) and/or fatty liver disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription